Related Experiment Video
Updated: Aug 11, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Current recommendations for the anticoagulation of patients with atrial fibrillation
1Department of Medicine, Ohio State University, Columbus, USA.
Insights
Atrial fibrillation (AF) significantly increases stroke risk. Anticoagulant therapy is recommended for most patients with nonrheumatic AF to prevent thromboembolic complications, according to current guidelines.
Area of Science:
- Cardiology
- Neurology
- Thrombosis
Background:
- Atrial fibrillation (AF) is a prevalent cardiac arrhythmia strongly linked to stroke.
- While anticoagulant benefits in AF with mitral stenosis are established, risks in nonrheumatic AF were historically unclear.
Purpose of the Study:
- To review studies on stroke risk in nonrheumatic AF.
- To evaluate the role and benefits of anticoagulant therapy for stroke prevention in AF patients.
Main Methods:
- Review of large clinical trials and published guidelines.
- Analysis of data on thromboembolic complication rates and treatment efficacy.
Main Results:
- Nonrheumatic AF is associated with a fivefold increase in stroke risk.
- Anticoagulants and aspirin demonstrate significant benefits in preventing thromboembolic events.
- Current guidelines advocate anticoagulation for most AF patients, excluding low-risk individuals.
Conclusions:
- Anticoagulant therapy is crucial for stroke prevention in the majority of nonrheumatic AF patients.
- Evidence supports the use of anticoagulants and aspirin for primary and secondary prevention of stroke in AF.
- Guidelines recommend broad anticoagulation strategies for AF patients at risk of stroke.
Abstract:
Atrial fibrillation (AF) is the most commonly encountered cardiac rhythm disorder and is strongly associated with stroke. The risk of stroke and the benefit of anticoagulant therapy in patients with AF associated with mitral stenosis has been well accepted. Until recently the risk of stroke and the role of anticoagulant therapy in patients with nonrheumatic AF was unclear. Over the past decade studies have shown an approximate fivefold increase in the risk of stroke in patients with nonrheumatic AF. The results of large clinical trials have shown a benefit of treatment with anticoagulants and, to a lesser extent, aspirin for both the primary and secondary prevention of thromboembolic complications. Other than patients with a low risk of thromboembolic complications (primarily young patients without clinical risk factors), current guidelines recommend anticoagulation of most patients with AF. The studies that form the basis for these recommendations and the currently published guidelines are reviewed.
Related Concept Videos
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis IV: Nursing Management
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

